Vilas Patwardhan

Vilas Patwardhan

Auto-generated profile, based on publicly available information

Vilas Patwardhan

Division of Gastroenterology, Hepatology, and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street Suite 8E, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
Aldo J. Montano-LozaAldo J. Montano-Loza
Aldo J. Montano-Loza
VRVincenzo Ronca
Vincenzo Ronca
MEMaryam Ebadi
Maryam Ebadi
BHBettina E. Hansen
Bettina E. Hansen
GHGideon Hirschfield
Gideon Hirschfield
YOYe Htun Oo
Ye Htun Oo

1 January 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
MVMarta Vuerich
Marta Vuerich
RHRasika Harshe
Rasika Harshe
LUIZA ABRAHAO FRANKLUIZA ABRAHAO FRANK
LUIZA ABRAHAO FRANK
SMSamiran Mukherjee
Samiran Mukherjee
BGBarbora Gromova
Barbora Gromova
Maria Serena LonghiMaria Serena Longhi
Maria Serena Longhi

Verified
Journal Article
Open access
PDF file
BFBenjamin Freedman
Benjamin Freedman
CDChristopher Danford
Christopher Danford
VPVilas Patwardhan
Vilas Patwardhan
ABAlan Bonder
Alan Bonder
The treatment of overlap syndromes is guided by small observational studies whose data have never been synthesized in a rigorous, quantitative manner. We conducted a systematic review and meta-analysis to evaluate the efficacy of available treatments for these rare and morbid conditions. We searched the literature for studies comparing ≥2 therapies for autoimmune hepatitis (AIH)-primary biliary cholangitis (PBC), AIH-primary sclerosing cholangitis (PSC), PBC-PSC, AIH-PBC-PSC, autoimmune cholangitis (AIC), or autoimmune sclerosing cholangitis (ASC) with respect to various clinical outcomes, including biochemical improvement and transplant-free survival. A total of 28 studies met the inclusion criteria for AIH-PBC, AIH-PSC, AIC, and ASC. AIH-PBC patients tended to experience more biochemical improvement with ursodeoxycholic acid (UDCA) + [corticosteroids and/or antimetabolites], i.e., “combination therapy”, than with corticosteroids ± azathioprine (RR = 4.00, 95% CI 0.93–17.18). AIH-PBC patients had higher transplant-free survival with combination therapy than with UDCA, but only when studies with follow-up periods ≤90 months were excluded (RR = 6.50, 95% CI 1.47–28.83). Combination therapy may therefore be superior to both UDCA and corticosteroids ± azathioprine for the treatment of AIH-PBC, but additional studies are needed to show this definitively and to elucidate optimal treatments for other overlap syndromes.

1 January 2023 in Hepatology Communications
Verified
Journal Article
Open access
MCMichael P. Curry
Michael P. Curry
HVHugo E. Vargas
Hugo E. Vargas
ABAlex S. Befeler
Alex S. Befeler
NPNikolaos T. Pyrsopoulos
Nikolaos T. Pyrsopoulos
VPVilas R. Patwardhan
Vilas R. Patwardhan
KJKhurram Jamil
Khurram Jamil
Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function. Liver transplantation remains the only curative treatment for decompensated cirrhosis. However, terlipressin, a vasopressin analog, successfully reverses HRS-1, and may improve patient survival while awaiting liver transplantation. Patients with higher baseline serum creatinine have a reduced response to treatment with terlipressin. These post hoc analyses examined pooled data from 352 patients with HRS-1 treated with terlipressin in 3 North American-centric, Phase III, placebo-controlled clinical studies (i.e. OT-0401, REVERSE, and CONFIRM)—across 3 serum creatinine subgroups (i.e. <3, ≥3–<5, and ≥5 mg/dL)—to further delineate their correlation with HRS reversal, renal replacement therapy-free survival, and overall survival. Serum creatinine was significantly associated with HRS reversal in univariate and multivariate logistic regression analyses (P<0.001). The incidence of HRS reversal inversely correlated with serum creatinine subgroup (<3 mg/dL, 49.2%; ≥3–<5 mg/dL, 28.0%; ≥5 mg/dL, 9.1%). At Day 30 follow-up, renal replacement therapy-free survival was significantly higher for patients with HRS-1 in the lower serum creatinine subgroups than in the higher subgroup (5 mg/dL; p=0.01). Terlipressin-treated patients with HRS-1, with a lower baseline serum creatinine level, had a higher overall survival (p<0.001) and higher transplant-free survival at Day 90 (p=0.04). Patients with HRS-1 and lower serum creatinine levels who were treated with terlipressin had higher HRS reversal and survival outcomes, highlighting the significant need to identify and treat patients with HRS-1 early when they often have lower serum creatinine levels, and likely a greater response to terlipressin.

23 February 2023 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
RBRomelia Barba
Romelia Barba
BFBryan William Ferrigno
Bryan William Ferrigno
EMEsli Medina-Morales
Esli Medina-Morales
CCCristina M. Castro
Cristina M. Castro
DGDaniela Goyes
Daniela Goyes
ABAlan Bonder
Alan Bonder
Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets. Cite this article as: Barba Bernal R, Ferrigno B, Medina Morales E, et al. Management of primary biliary cholangitis: Current treatment and future perspectives. Turk J Gastroenterol. 2023;34(2):89-100.

1 January 2016 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
VPVilas R. Patwardhan
Vilas R. Patwardhan
JFJoseph Feuerstein
Joseph Feuerstein
NSNeil Sengupta
Neil Sengupta
JLJeffrey J. Ba Lewandowski
Jeffrey J. Ba Lewandowski
RTRoy Bsc Tsao
Roy Bsc Tsao
SSSunil G. Sheth
Sunil G. Sheth
Goals: To objectively assess when gastroenterology (GI) fellows achieve technical competency to perform colonoscopy independently. Background: New guidelines to assess the procedural competency of GI fellows in training have been developed. Although comprehensive, they do not account for the quality metrics to which independently practicing gastroenterologists are held. Study: We performed a prospective study examining consecutive colonoscopies performed by GI fellows from November 2013 through March 2014 at an academic medical center. Using a brief postprocedure questionnaire and the online medical record, we measured rates of independent fellow cecal intubation rate (CIR), insertion time to the cecum (cecal IT), and independent polypectomy rate. Our secondary outcomes were adenoma detection rate and polyp detection rate. Results: A total of 898 colonoscopies performed by 10 GI fellows were analyzed. In the multivariate analysis, CIR [odds ratio (OR)=1.29, P=0.012], cecal IT (β-coefficient=0.19, P=0.006), and rates of unassisted independent snare polypectomy (OR=1.36, P90%, cecal IT between 7 and 10 minutes, and independent polypectomy rate of 90% with further improvement in cecal IT to 95% after 700 cases. Conclusions: Current procedural recommendations for fellowship training may underestimate the technical skill necessary for independent GI practice upon completion of fellowship. Technical proficiency in snare polypectomy may lag behind proficiency in cecal intubation.